Lilly's revenue gains have helped its stock to roar higher.Eli Lilly (LLY -3.36%) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro and Zepbound. Together, these drugs are adding billions of dollars to the company's top line, helping Lilly report double-digit gains in quarterly revenue.Today Eli Lilly shares the market with rival Novo Nordisk, which sells two weight loss drugs that wor ...

Pfizer (PFE) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The upward trend in estimate revisions for this drugmaker reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near ...

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores h ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and ...

Pfizer's efforts are starting to bear fruit.Pfizer (PFE 0.36%) is one of the most successful pharmaceutical companies ever. In 2022, it brought in more than $100 billion in revenue -- a record for itself and for the entire industry. Of course, a lot of this was due to an unprecedented situation -- the COVID-19 pandemic -- and two products to address it: Pfizer's coronavirus vaccine and treatment.As demand for these treatments dropped in later pandemic times, though, it was clear Pfizer needed a new growth d ...

no_limit_pictures My Thesis Update I initiated coverage on Pfizer (NYSE:PFE) stock with a "Buy" rating, stating that the company's low valuation and strong product pipeline make it the ultimate buying opportunity for income investors in the healthcare sector. In early May, I updated my thesis, noting that the market started to finally wake up on PFE's prospects of continued growth from non-COVID drugs and potential margin expansion. Back in May, I anticipated that PFE's dividend stability, recent revenu ...

On Tuesday, Pfizer Inc. PFE reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46.The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion.Truist Securities sees the strong demand growth as highly encouraging and, at current levels, Pfizer shares are very attractive given the company’s diverse portfolio that is gaining momentum, effective cost-cutting initiatives, and a commitment ...

Trevor Williams In the tale of two large-cap pharma stocks it was a contrast in expectations, and performance on Tuesday morning, July 30 ’24, as Pfizer (NYSE:PFE, NEOE:PFE:CA) , with very low expectations coming into the release, but technically improved in the last month, sharply contrasted with Merck, which disappointed coming into the release, after seeing good growth around Keytruda, and Gardasil in prior quarters. As of last Friday, July 26th ’24, Merck was +16.31% YTD as of Friday night’s close, ...

Key TakeawaysPfizer raised the midpoint of its full-year revenue and adjusted earnings per share (EPS) guidance.The company posted its first quarter of year-over-year revenue growth since the fourth quarter of 2022, when COVID vaccine and medication revenue peaked.Pfizer also said it launched a manufacturing optimization program that it projects will save $1.5 billion by the end of 2027. Pfizer (PFE) shares rose Tuesday after the pharmaceutical giant beat second-quarter revenue expectations and raised its f ...

Second Quarter 2024 Earnings Teleconference July 30, 2024 Breakthroughs that change patients' lives ® Introduction Francesca DeMartino Chief Investor Relations Officer, Senior Vice President Forward-Looking Statements and Non-GAAP Financial Information l Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We include f ...